Although much work has focused on the elucidation of somatic alterations that drive the
development of acute leukaemias and other haematopoietic diseases, it has become …

Juvenile myelomonocytic leukemia (JMML) is a unique clonal hematopoietic disorder of
early childhood. It is classified as an overlap myeloproliferative/myelodysplastic neoplasm …

Myelodysplastic syndromes (MDS) are clonal diseases defined by clinical, morphologic, and
genetic features often shared by related myeloid disorders. The diagnostic boundaries …

Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative therapy for
most children with juvenile myelomonocytic leukemia (JMML). Novel therapies controlling …

Cytosine methylation is an important DNA epigenetic modification. In vertebrates,
methylation occurs at CpG sites, which are dinucleotides where a cytosine is immediately …

Purpose: Known clinical and genetic markers have limitations in predicting disease course
and outcome in juvenile myelomonocytic leukemia (JMML). DNA methylation patterns in …

Juvenile myelomonocytic leukemia (JMML) is a unique clonal hematopoietic disorder of
early childhood characterized by hyperactivation of the RAS signal transduction pathway …

Precision oncology aims to tailor clinical decisions specifically to patients with the objective
of improving treatment outcomes. This can be achieved by leveraging omics information for …

Juvenile myelomonocytic leukemia (JMML) is a rare pediatric leukemia characterized by
mutations in five canonical RAS pathway genes. The diagnosis is made by typical clinical …

The human adaptive immune system recognizes almost all the pathogens that we encounter
and all the tumor antigens that may arise during our lifetime. Primary immunodeficiencies …